Literature DB >> 14718798

Mechanism of taxane neurotoxicity.

Hiroki Hagiwara1, Yoshihide Sunada.   

Abstract

The two taxanes (paclitaxel and docetaxel) are widely employed in standard antineoplastic practice. Although these agents are now well established, some toxic side effects have been reported. Toxicity of these agents includes bone marrow suppression (principally neutropenia), hypersensitivity reactions, cutaneous reactions, edema and neurotoxicity. The most prominent neurotoxicity is a sensory neuropathy. Controlling neuropathy is crucial for maintaining the quality of life of patients because it is usually persistent and hard to manage. The precise mechanism for taxane-induced neuropathy is still unknown. The taxanes are known to promote aggregation of intracellular microtubules. Abnormal aggregation of microtubules in the neuronal cells may cause this neuropathy. In addition, the taxanes have been suggested to have intrinsic toxicity and directly injure the cells. A better understanding of the mechanism for this neuropathy may improve the quality of life of patients who undergo taxane antineoplastic therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718798     DOI: 10.1007/bf02968008

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  47 in total

Review 1.  Herbal medicine as inducers of apoptosis in cancer treatment.

Authors:  Elham Safarzadeh; Siamak Sandoghchian Shotorbani; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2014-08-25

2.  Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study.

Authors:  Tulay Kus; Gokmen Aktas; Mehmet Emin Kalender; Alper Sevinc; Seval Kul; Ali Suner; Esra Ulker; Celaletdin Camci
Journal:  Support Care Cancer       Date:  2015-08-18       Impact factor: 3.603

3.  Electrophysiological evaluation of visual pathways in paclitaxel-treated patients.

Authors:  V Scaioli; A Caraceni; C Martini; S Curzi; G Capri; G Luca
Journal:  J Neurooncol       Date:  2005-08-25       Impact factor: 4.130

4.  Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy.

Authors:  Yan Li; Haijun Zhang; Hongmei Zhang; Alyssa K Kosturakis; Abdul Basit Jawad; Patrick M Dougherty
Journal:  J Pain       Date:  2014-04-19       Impact factor: 5.820

5.  MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy.

Authors:  Yan Li; Hongmei Zhang; Alyssa K Kosturakis; Ryan M Cassidy; Haijun Zhang; Ross M Kennamer-Chapman; Abdul Basit Jawad; Cecilia M Colomand; Daniel S Harrison; Patrick M Dougherty
Journal:  Brain Behav Immun       Date:  2015-06-09       Impact factor: 7.217

Review 6.  The use of nanoparticulates to treat breast cancer.

Authors:  Xiaomeng Tang; Welley S Loc; Cheng Dong; Gail L Matters; Peter J Butler; Mark Kester; Craig Meyers; Yixing Jiang; James H Adair
Journal:  Nanomedicine (Lond)       Date:  2017-09-04       Impact factor: 5.307

7.  The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells.

Authors:  Cory T Zumbar; Aisulu Usubalieva; Paul D King; Xiaohui Li; Caroline S Mifsud; Hailey M Dalton; Muge Sak; Sara Urio; William M Bryant; Joseph P McElroy; George Farmer; Norman L Lehman
Journal:  J Neurooncol       Date:  2018-02-02       Impact factor: 4.130

8.  Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376).

Authors:  James I Geller; Donna Wall; John Perentesis; Susan M Blaney; Mark Bernstein
Journal:  Pediatr Blood Cancer       Date:  2009-03       Impact factor: 3.167

Review 9.  Taxane anticancer agents: a patent perspective.

Authors:  Iwao Ojima; Brendan Lichtenthal; Siyeon Lee; Changwei Wang; Xin Wang
Journal:  Expert Opin Ther Pat       Date:  2015-12-10       Impact factor: 6.674

10.  Melatonin, a promising role in taxane-related neuropathy.

Authors:  Z Nahleh; J Pruemer; J Lafollette; S Sweany
Journal:  Clin Med Insights Oncol       Date:  2010-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.